Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.37 |
| ▸ | HTR5A | P47898 | 2/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813452 | 1.00 | AR (0.43) | ARHTR2CHTR2AESR1ESR2 | |
| SCHEMBL14943839 | 1.00 | AR (0.43) | ARHTR2CHTR2AESR1ESR2 | |
| SCHEMBL29644324 | 1.00 | AR (0.43) | ARHTR2CHTR2AESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8597665 | 0.98 | AR (0.42) | ARHTR2CHTR2AESR1ESR2 | |
| SCHEMBL4102066 | 0.87 | HTR2C (0.44) | ARHTR2CHTR2AHTR1DHTR1B | |
| SCHEMBL29529402 | 0.81 | LMNA (0.46) | ARHTR2CHTR2AALDH1A1HTR5A | |
| SCHEMBL8937088 | 0.81 | LMNA (0.46) | ARHTR2CHTR2AALDH1A1HTR5A | |
| SCHEMBL30681298 | 0.81 | LMNA (0.46) | ARHTR2CHTR2AALDH1A1HTR5A | |
| SCHEMBL4133012 | 0.80 | AR (0.40) | ARESR1ESR2ALDH1A1HTR5A | |
| SCHEMBL13091374 | 0.80 | AR (0.40) | ARESR1ESR2ALDH1A1HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041253-B | Method for synthesizing diphenyl-2-pyridylmethane derivative | 浙江九洲药业股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119707617-A | Method for reducing alkyne into alkene by using water as hydrogen source | 长春工业大学 | 2025-03-28 | — | — | CN | claimed |
| CN-116041253-A | Method for synthesizing diphenyl-2-pyridylmethane derivative | 浙江九洲药业股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | claimed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | claimed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | claimed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | claimed |
| EP-0674232-B1 | Recording sheets | XEROX CORP (US) | 2000-05-31 | — | — | EP | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0819677-A1 | Process for the preparation of optically active compounds | CHINOIN Gyògyszer és Vegyészeti Termékek Gyára RT. (HU) | 1998-01-21 | — | — | EP | claimed |
| EP-0808835-A1 | Process for the preparation of optically active compounds | CHINOIN Gyògyszer és Vegyészeti Termékek Gyára RT. (HU) | 1997-11-26 | — | — | EP | claimed |
| US-5663022-A | Recording sheets | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0674232-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-4301289-A | Process for 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1981-11-17 | — | — | US | claimed |
| US-4301288-A | Process for 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1981-11-17 | — | — | US | claimed |
| JP-1128982-A | — | — | None | — | — | JP | disclosed |
| US-3985882-A | ADMISTERING | RIKER LABORATORIES, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3969463-A | MICROBIOCIDE | RIKER LABORATORIES, INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | AR 3087/4885HTR2C 4020/4885HTR2A 4357/4885 |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | AR 4166/4885HTR2C 2371/4885HTR2A 2521/4885 |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE4B | AR 994/4885HTR2C 2418/4885HTR2A 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.